Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

To join this study, you would generally need to have advanced cancer that has spread or is difficult to treat with standard approaches. Your doctors would need to confirm that your specific cancer has certain characteristics, such as the Nectin-4 protein on its cells for some parts of the study, or if it has progressed after previous treatment.

You would also need to be at least 18 years old and generally well enough to take part, with a life expectancy of at least 12 weeks. Your cancer would need to be measurable, meaning doctors can track its size. For some specific parts of the study, there are extra requirements depending on your cancer type and what treatments you've had before. For example, some parts are specifically for bladder cancer that has progressed after certain prior treatments.

It's important to remember that these are just general guidelines. The study team will review your full medical history and perform tests to confirm if you meet all the detailed criteria to ensure the study is safe and appropriate for you.

If you decide to take part in this study, you would receive the study treatment, either BT8009 alone or with pembrolizumab. The medication would typically be given through a drip (intravenous infusion). Depending on which part of the study you are in, you might receive treatment weekly, every two weeks, or on specific days within a three-week cycle. You would have regular visits to the clinic for assessments, including blood tests, scans (like CT or MRI) to check your cancer, and check-ups with the study doctors and nurses to monitor your health and any side effects. The total length of your participation would depend on how your cancer responds to the treatment and your general health, but it could involve many months of regular visits and follow-up after the treatment stops.